MAP2K7 and melanoma: Additionally, fibroblast growth factor 1 (FGF1) inhibitors have been studied in this context, as the upregulation of FGF1 has been implicated in resistance to BRAF and MEK inhibition, and its blockade may help to resensitize melanoma cells to targeted therapy.